Medicare Enrolled
Dr. Srinivas Kodali, M.D
Hematology & Oncology · Beaumont, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Kodali from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kodali? Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kodali
Dr. Srinivas Kodali is a hematology & oncology in Beaumont, TX, with 16 years in practice. Based on federal Medicare data, Dr. Kodali performed 88,663 Medicare services across 3,916 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kodali received a total of $4,527 from 48 pharmaceutical and/or device companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kodali is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 16 years in practice▲ Top 9% volume in TX$ $4,527 industry payments
Medicare Practice Summary
Medicare Utilization ↗88,663
Medicare services
Top 9% in TX for hematology & oncology
3,916
Unique beneficiaries
$8
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~5,541 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Iron sucrose injection (Venofer) | 21,000 | $0 | $2 |
| Darbepoetin injection (Aranesp) for anemia | 10,890 | $2 | $20 |
| Iron infusion (Feraheme) | 10,710 | $0 | $5 |
| Paclitaxel chemotherapy injection | 9,284 | $0 | $8 |
| Anti-nausea injection (fosaprepitant) | 7,950 | $0 | $5 |
| Pembrolizumab injection (Keytruda) | 6,800 | $42 | $137 |
| Dexamethasone injection (steroid) | 2,970 | $0 | $1 |
| Epoetin alfa injection (Procrit) for anemia | 2,450 | $6 | $51 |
| Epoetin alfa injection (Retacrit) for anemia | 1,722 | $6 | $28 |
| Complete blood count (CBC) with differential | 1,633 | $8 | $36 |
| Comprehensive metabolic blood panel | 1,420 | $10 | $64 |
| Contrast dye for imaging (iodine-based) | 1,400 | $0 | $3 |
| Denosumab injection (Prolia/Xgeva) | 1,320 | $18 | $66 |
| Injection, granisetron hydrochloride, 100 mcg | 1,010 | $0 | $24 |
| Office visit, established patient (30-39 min) | 874 | $88 | $368 |
| Anti-nausea injection (Aloxi/palonosetron) | 870 | $1 | $114 |
| Office visit, established patient (20-29 min) | 827 | $62 | $250 |
| Blood draw (venipuncture) | 516 | $8 | $20 |
| Iron level test | 417 | $6 | $27 |
| Iron binding capacity test | 417 | $9 | $35 |
| Drug injection, under skin or into muscle | 377 | $10 | $96 |
| Injection of additional new drug or substance into vein | 366 | $11 | $108 |
| Hospital follow-up visit, moderate complexity | 341 | $59 | $247 |
| Administration of chemotherapy into vein, 1 hour or less | 330 | $94 | $707 |
| Microscopic examination for white blood cells with manual cell count | 281 | $4 | $22 |
| Complete blood count (CBC), automated | 281 | $6 | $34 |
| Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | 231 | $21 | $157 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 178 | $45 | $313 |
| Injection, carboplatin, 50 mg | 154 | $2 | $300 |
| Hospital follow-up visit, high complexity | 150 | $88 | $357 |
| Reticulated (young) platelet measurement | 144 | $35 | $143 |
| Lactate dehydrogenase (enzyme) level | 127 | $6 | $31 |
| Injection, diphenhydramine hcl, up to 50 mg | 123 | $1 | $7 |
| Blood count, hemoglobin | 111 | $2 | $14 |
| Unclassified drugs | 88 | $1 | $8 |
| New patient office visit (45-59 min) | 83 | $110 | $565 |
| Administration of chemotherapy into vein, each additional hour | 73 | $19 | $161 |
| Administration of additional new drug or substance into vein, 1 hour or less | 73 | $46 | $344 |
| Enhancing oncology model (eom) monthly enhanced oncology services (meos) payment for eom enhanced services | 73 | $73 | $70 |
| Injection, prochlorperazine, up to 10 mg | 72 | $2 | $47 |
| Ferritin level test (iron stores) | 68 | $13 | $60 |
| Initial hospital admission, high complexity | 62 | $125 | $694 |
| Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries | 48 | $89 | $657 |
| Stool analysis for blood to screen for colon tumors | 44 | $4 | $24 |
| Red blood count, automated test | 41 | $4 | $23 |
| Nuclear medicine study from skull base to mid-thigh with ct scan | 40 | $1,070 | $4,802 |
| Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | 39 | $24 | $145 |
| Uric acid level test | 32 | $4 | $25 |
| Administration of additional new drug or substance into vein using push technique | 30 | $41 | $289 |
| Office visit, established patient, complex (40-54 min) | 24 | $135 | $496 |
| Infusion, normal saline solution, sterile (500 ml = 1 unit) | 21 | $1 | $19 |
| Biopsy and aspiration of bone marrow sample for diagnosis | 18 | $131 | $523 |
| New patient office visit, complex (60-74 min) | 17 | $146 | $709 |
| Infusion, normal saline solution , 1000 cc | 17 | $2 | $19 |
| Blood creatinine level | 13 | $5 | $31 |
| Urea nitrogen level to assess kidney function, quantitative | 13 | $4 | $24 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
12.6% high complexity
78.1% medium
9.3% routine
Industry Payment Transparency
Open Payments through 2024 ↗$4,527
Total received (2018-2024)
Avg $647/year across 7 years
Top 45% in TX for hematology & oncology
48
Companies
186
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$3,861 (85.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$666 (14.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024$2,642
2023$1,112
2022$151
2021$23
2020$17
2019$365
2018$217
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
GENZYME CORPORATION
$302
Janssen Biotech, Inc.
$298
Boehringer Ingelheim Pharmaceuticals, Inc.
$258
AstraZeneca Pharmaceuticals LP
$243
Merck Sharp & Dohme LLC
$203
Astellas Pharma US Inc
$189
Novartis Pharmaceuticals Corporation
$186
BeiGene USA, Inc.
$171
PFIZER INC.
$168
GlaxoSmithKline, LLC.
$159
SOBI, INC
$124
E.R. Squibb & Sons, L.L.C.
$121
Gilead Sciences, Inc.
$119
Puma Biotechnology, Inc.
$118
TAIHO ONCOLOGY, INC.
$117
Lilly USA, LLC
$114
Seagen Inc.
$111
Apellis Pharmaceuticals, Inc.
$110
Celgene Corporation
$110
Incyte Corporation
$106
Amgen Inc.
$100
Karyopharm Therapeutics Inc.
$93
Boston Scientific Corporation
$84
SUN PHARMACEUTICAL INDUSTRIES INC.
$73
PUMA BIOTECHNOLOGY, INC.
$72
Eisai Inc.
$65
ADC Therapeutics America, Inc.
$62
Exelixis Inc.
$61
Mirati Therapeutics, Inc.
$54
Regeneron Healthcare Solutions, Inc.
$53
Janssen Pharmaceuticals, Inc
$48
Daiichi Sankyo Inc.
$45
Genmab U.S., Inc.
$39
Rigel Pharmaceuticals, Inc.
$34
EISAI INC.
$32
Blueprint Medicines Corporation
$29
Tempus AI, Inc
$29
JAZZ PHARMACEUTICALS INC.
$28
Deciphera Pharmaceuticals Inc.
$28
Adaptive Biotechnologies Corporation
$25
ABBVIE INC.
$24
Sun Pharmaceutical Industries Inc.
$23
EMD Serono, Inc.
$22
PharmaEssentia USA Corporation
$21
Genentech USA, Inc.
$19
Ipsen Biopharmaceuticals, Inc
$17
Seattle Genetics, Inc.
$12
Takeda Pharmaceuticals U.S.A., Inc.
$12
Top 3 companies account for 18.9% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · AYVAKIT · Alecensa · BAVENCIO · BESREMI · BRUKINSA · Cabometyx · DARZALEX · Doptelet · ELAHERE · ELIQUIS · ENHERTU · ENJAYMO · ERLEADA · Empaveli · Enhertu · Epkinly · Erleada · Fabhalta · GILOTRIF · IBRANCE · IMFINZI · INLYTA · JAKAFI · JEVTANA · KEYTRUDA · KRAZATI · LIBTAYO · LONSURF · LUTATHERA · Lenvima · MONJUVI · NERLYNX · NINLARO · Nerlynx · OJJAARA · OPDIVO · OPDUALAG · Odomzo · Onivyde · PADCEV · PLUVICTO · Padcev · Pomalyst · QINLOCK · REBLOZYL · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · TAGRISSO · TECVAYLI · Trodelvy · VERZENIO · VONJO · XPOVIO · XT CDX · XTANDI · Xospata · Xtandi · YONSA · ZEPZELCA · Zydelig · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (85%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $5 per 100 Medicare services performed
Geographic Context
Hematology & Oncologys within 10 mi
3
Per 100K population
1.2
County median income
$59,934
Nearest hospital
BAPTIST BEAUMONT HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Kodali is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), and low-engagement industry engagement, with 16 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Kodali experienced with iron sucrose injection (venofer)?
Based on Medicare claims data, Dr. Kodali performed 21,000 iron sucrose injection (venofer) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kodali receive payments from pharmaceutical companies?
Yes. Dr. Kodali received a total of $4,527 from 48 companies across 186 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kodali's costs compare to other hematology & oncologys in Beaumont?
Dr. Kodali's average Medicare payment per service is $8. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kodali) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncologys in Beaumont
Browse hematology & oncologys in Beaumont ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncologys in TX
Hematology & Oncologys ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncologys in TX
Which TX hematology & oncologys receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Janssen Biotech, Inc. Payments to Doctors
See all physicians who received payments from Janssen Biotech, Inc..
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc..
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology